Do commonly used clinical trial designs reflect clinical reality?

Haematologica

Volumn 94, Issue 10, 2009, Pages 1435-1439

  Estey, Elihu ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Leukemia; MLL; Proteins

Indexed keywords

ARSENIC TRIOXIDE; CLADRIBINE; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IMATINIB; RETINOIC ACID; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BAYES THEOREM; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; GENETIC HETEROGENEITY; HAIRY CELL LEUKEMIA; HUMAN; MEDICAL PRACTICE; PHYSICIAN; PROGNOSIS; REVIEW;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 70349638629     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.011411     Document Type: Review

References (24)

1. Baer M, George S, Dodge R, O'Loughlin KL, Minderman H, Caligiuri MA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-1232 (Pubitemid 34864276)
2. Rowe J, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485 (Pubitemid 38140076)
3. van der Holt B, Lowenberg B, Burnett A, Knauf WU, Shepherd J, Piccaluga PP, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia, in relation to MDR1 status at diagnosis. Blood 2005;106:2646-2654 (Pubitemid 41510736)
4. Berger J, Berry D. Statistical analysis and the illusion of objectivity. Am Sci 1988;76:159-165.
5. Berry DA, Stangl DK, editors. Bayesian Biostatistics. New York: Marcel Dekker; 1996.
6. Goodman SA. Toward Evidence-Based Medical Statistics,1: the p-value fallacy. Ann Intern Med 1999; 130:996-1004.
7. Goodman SA. Toward Evidence-Based Medical Statistics, 2: the Bayes factor. Ann Intern Med 1999;130: 1005-1013
8. Hilsenbeck S, Clark G, McGuire W. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992;22:197-206.
9. Altman D, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 1994;86:829-835
10. Berry D, Eick S. Adaptive assignment vs. balanced randomization in clinical trials: a decision analysis. Stat Med 1995;14:231-246
11. Thall P, Wathan J. Practical Bayesian adaptive randomization in clinical trials. Eur J Cancer 2007;43:859-866 (Pubitemid 46366693)
12. Giles F, Kantarjian H, Cortes J, Garcia-Manero G, Verstovsek S, Faderl S, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003;21:1722-1727 (Pubitemid 46638583)
13. Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med 2006;25:55-70.
14. Simon R. Optimal two-stage designs for phase 2 clinical trials. Controlled Clin Trials 1989:10:1-10. (Pubitemid 19099520)
15. Thall PF, Simon R. Incorporating historical control data in planning phase 2 clinical trials. Stat Med 1990;9:215-228 (Pubitemid 20252730)
16. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907
17. Wathen J, Thall PF, Cook J, Estey E. Accounting for patient heterogeneity in phase 2 clinical trials. Stat Med 2008;27:2802-2815 (Pubitemid 351982677)
18. Thall P, Lee S. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer 2003;13:251-261 (Pubitemid 38222572)
19. Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res 2004;10:4645-4651 (Pubitemid 38955514)
20. Thall PF, Nguyen HQ, Estey E. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics 2008;64:1126-1136
21. Estey E, Garcia-Manero G, Giles F, Cortes J, O'Brien S, Kantarajian H. Clinical relevance of CRp in untreated AML. Blood 2005:106:Abstract 541.
22. Estey E, Thall PF. New designs for phase 2 trials. Blood 2003;102:442-448
23. Thall PF, Estey E, Sung H. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Invest New Drugs 1999:17:155-167
24. Thall PF, Estey EA. Bayesian strategy for screening cancer treatments prior to phase 2 clinical evaluation. Stat Med 1993; 12:1197-1211